rrr
Research institute for biological safety problems

BIOPHARMACEUTICAL PLANT «OtarBioFarm»

On June 23, 2021, the Department for Registration and Land Cadastre of the branch of the non-profit joint-stock company «State Corporation «Government for Citizens» for the Zhambyl region» of the Kordai district registered the Limited Liability Company «OtarBioFarm», the founder of which is the Republican State Enterprise on the right of economic management «Research Institute for Biological Safety Problems» of the Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan. Zakir Dzhaparovich Yershebulov was appointed the head of «OtarBioFarm» LLС.

After launching and reaching full capacity, the Biopharmaceutical plant «OtarBioFarm» will be the first large full-cycle plant in the Republic of Kazakhstan for the production of immunobiological drugs (vaccines) against particularly dangerous infectious diseases according to the international standard of Good Manufacturing Practice (GMP), including the QazVac coronavirus vaccine.

Congratulations to OtarBioFarm LLC on this historic event!

We wish you fruitful implementation of creative ideas in scientific and production activities, success in implementing the most daring projects, determination in achieving great goals for the benefit of ensuring the biological safety of the Republic of Kazakhstan!

QazCoVac-P – COVID-19 SUBUNIT VACCINE IS ON THE WHO LIST OF CANDIDATE VACCINES FOR PHASE 1/2 CLINICAL TRIALS

On June 22, 2021, Kazakhstan’s second COVID-19 vaccine QazCoVac-P (subunit) was officially included in the list of candidate vaccines of the World Health Organization for conducting phase 1/2 clinical trials.

https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines

Earlier, on June 18, 2021, the design of the clinical trial was officially posted on the website ClinicalTrials.gov under Identifier number: NCT04930003

https://clinicaltrials.gov/ct2/show/NCT04930003?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2

 

CLINICAL STUDIES OF COVID-19 SUBUNIT VACCINE DEVELOPED BY RIBSP SCIENTISTS HAVE BEGUN

On June 15, 2021, clinical studies of COVID-19 domestic subunit vaccine with the involvement of volunteers from 18 to 50 years old in Taraz city multi-field hospital have begun.

RSE on REM «Research Institute for Biological Safety Problems» of the Committee of Science of the Ministry of Education and Science of the Republic of Kazakhstan obtained permission from the Ministry of Health of the Republic of Kazakhstan to conduct phase I and II clinical studies of a new vaccine drug for the prevention of COVID-19 – QazCoVac-P  subunit vaccine based on artificially synthesized proteins of the SARS-CoV-2 coronavirus.

This is the second vaccine of RIBSP that has successfully passed preclinical trials in a specialized facility of the Ministry of Health of the Republic of Kazakhstan and has shown its safety.

Due to the use of modern molecular biology technologies, the developers were able to get strains that produce RBD- and N-proteins of the SARS-CoV-2 coronavirus, which are recognized by the immune system.

To ensure the safety of the vaccine, all the stages of complex purification of the produced proteins were carried out and quality control was passed. They do not contain a whole virus.

On the 14th day after intramuscular administration of the second dose, the vaccine stimulates immunity in the body of vaccinated laboratory animals.

Subunit vaccines, like inactivated vaccines, do not contain live components of the pathogen and are very safe.

The adjuvant, contained in the vaccine, effectively stimulates the immune response, without having a negative effect on the body of the vaccinated person, since this vaccine contains only the necessary antigens, and does not include all the other components of the virus. Side effects after the subunit vaccine are less common. Examples of this type of vaccine are influenza, hepatitis B, pneumococcal, meningococcal, hemophilic infections and other vaccines.

Successful clinical studies will make it possible to expand the population of those vaccinated with a subunit vaccine and accelerate the formation of collective immunity to coronavirus in the country’s population.

MEETING OF THE WHO CHAIRWOMAN IN KAZAKHSTAN, CAROLINE CLARINVAL, WITH THE DIRECTOR-GENERAL OF THE RESEARCH INSTITUTE FOR BIOLOGICAL SAFETY PROBLEMS

On May 28, 2021, the Chairwoman of the World Health Organization (WHO) in Kazakhstan, Caroline Clarinval, met with the Director General of the Research Institute for Biological Safety Problems.

During the meeting, which was also attended by employees of the Ministry of Foreign Affairs of the Republic of Kazakhstan, the possibility of registering the Kazakh QazVac vaccine with the WHO was considered.

WHO is the most important partner of the authorities, as the organization develops technical recommendations as part of the response to COVID-19, as well as provides other technically qualified resources in such areas of health care as epidemiology, risk communication, logistics, and others, which is an important factor today.

At the end of the meeting, the parties decided to cooperate on the registration of Kazakhstan’s QazVac vaccine.

 

                                                                                                   Illustrative photo: from open sources